Added to YB: 2025-07-15
Pitch date: 2025-07-11
BPMC [neutral]
Blueprint Medicines Corporation
+0.12%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally.
Market Cap
$8.4B
Pitch Price
$129.30
Price Target
N/A
Dividend
N/A
EV/EBITDA
-60.94
P/E
-52.77
EV/Sales
14.58
Sector
Biotechnology
Category
special_situation
Quick glance at BPMC CVR - why institutions hate it and you shouldn´t
BPMC (special sit overview): Sanofi acquisition at $129/sh + CVR worth up to $6 ($2 for Phase 3 initiation, $4 for FDA approval) for BLU-808 KIT inhibitor. CVR trades at ~$0.33-0.44 but worth ~$1.13 based on 40% Phase 3 probability × 65% approval chance. Undervalued due to capital lockup requirements and long timeline (2-7 years). Tender expires July 16.
Read full article (4 min)